Advertisement

Prostate Cancer Urology

Impact of ADT Duration on Time to TR and Metastasis-Free Survival in Prostate Cancer

Sep 30, 2024

The following is a summary of “Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Rando...

Late Biochemical Recurrence in Patients with PCa After Radical Prostatectomy

Sep 30, 2024

The following is a summary of “Risk of Biochemical Recurrence and Metastasis in Prostate Cancer Patients Treated with Radical Prostatectomy After a 10-year Disease-free Interval,” published in the...

Optimal Therapeutic Sequencing & Intensified Treatment Strategies in mCRPC

Sep 27, 2024

The following is a summary of “Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review,” published in the September 2024 issue o...

VR for Enhancing Patient Understanding in Localized Prostate Cancer and Surgical Planning

Sep 27, 2024

The following is a summary of “Virtual Reality as an Adjunct to traditional patient counseling in Patients with newly-diagnosed localized prostate cancer,” published in the September 2024 issue of...

Evidence-Based Guidelines for Workup and Salvage Treatment of IPR-PC

Sep 26, 2024

The following is a summary of “American Radium Society Appropriate Use Criteria for the Workup and Treatment of Local Intraprostatic Recurrence of Prostate Cancer Following Definitive Radiotherapy,â...

Predictive Modeling of Incidental Prostate Cancer Risk in Benign Prostatic Hyperplasia Surgery

Sep 26, 2024

The following is a summary of “Incidental Prostate Cancer in Patients Undergoing Surgery for Benign Prostatic Hyperplasia: A Predictive Model,” published in the September 2024 issue of Urology by ...

Role of Serial mpMRI and PSA Increase in Upgrading PIRADS Lesions

Sep 24, 2024

The following is a summary of “Natural history of PIRADS-2 lesions on serial multiparametric magnetic resonance imaging: Real-life data from an Academic Center,” published in the September 2024 is...

Outcomes of Salvage Treatments for Recurrent Prostate Cancer

Sep 24, 2024

The following is a summary of “Salvage local treatment for recurrent prostate cancer after focal therapy: A systematic review and meta-analysis,” published in the September 2024 issue of Urology b...

Liquid Biopsy Predicts Docetaxel Futility & Identifies Resistance Biomarkers in mCRPC

Sep 20, 2024

The following is a summary of “Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial,” published in...

Comparative Outcomes of HoLEP in Patients Holding vs. Continuing Antiplatelet/Anticoagulation Therapy

Aug 31, 2024

The following is a summary of “To Hold or Continue Blood Thinners? A Retrospective Analysis on Outcomes of Holmium Laser Enucleation of the Prostate (HoLEP) in Patients who Either Held or Continued ...

Neoadjuvant Chemohormonal Therapy Aids Locally Advanced Prostate Cancer

May 21, 2024

For patients with locally advanced prostate cancer, neoadjuvant chemohormonal therapy (NCHT) is beneficial for biochemical progression-free survival (bPFS), according to a study published in The Jour...

Digital Rectal Exam Has Low Diagnostic Value for Prostate Cancer

Mar 05, 2024

Digital rectal examination (DRE) exhibits low diagnostic value as an independent test and supplementary measure to prostate-specific antigen (PSA) for detection of prostate cancer, according to a stud...

Plant-Based Food Intake Linked to Better QoL in Prostate Cancer

Mar 05, 2024

Among patients with prostate cancer, greater consumption of plant-based foods is associated with higher scores in quality-of-life domains, according to a study published in Cancer. Stacy Loeb, MD, PhD...

Prostate Cancer among Patients Undergoing Radical Cystoprostatectomy for Bladder Cancer in the Department of Urology in a Tertiary Care Centre.

Feb 12, 2024

Prostate cancer is the most common malignancy in men and remains one of the most prevalent and least understood of all human malignancies. Bladder cancer is the most frequently diagnosed cancer in Chi...

The immediate effects of private equity acquisition of urology practices on the management of newly diagnosed prostate cancer.

Jan 15, 2024

Some worry that physician practices acquired by private equity may increase the use of services to maximize revenue. We assessed the effects of private equity acquisition on spending, use of treatment...

Black Men More Likely Than Whites to Have Prostate Cancer

Jan 05, 2024

At any given prostate-specific antigen (PSA) level, Black men were more likely than White men to develop prostate cancer, according to a study published in Cancer. Kyung Min Lee, PhD, and colleagues p...

In-office dispensing of oral targeted agents by urology practices in men with advanced prostate cancer.

Oct 09, 2023

Management of men with advanced prostate cancer has evolved to include urologists, made possible by oral targeted agents (eg, abiraterone or enzalutamide) that can be dispensed directly to patients in...

Family History of Hereditary Cancer Syndrome Increases Risk for Prostate Cancer Progression

Aug 03, 2023

Study results indicate that family history of hereditary cancer syndrome appears to increase the risk for prostate cancer progression. Family history (FH) of malignancies, such as breast, ovari...

PMSA PET Offers Patients With Prostate Cancer More Precise Diagnosis

May 30, 2023

Christopher DiBlasio, MD, board-certified urologist and urologic surgeon, spoke with Physician’s Weekly about PMSA PET, an effective and precise technology for localizing metastatic prostate cancer....

Effects of In-office Dispensing by Single-specialty Urology Practices on Management of Advanced Prostate Cancer.

May 08, 2023

We examine changes in the volume of patients with advanced prostate cancer and prescriptions for abiraterone and enzalutamide among urology practices with and without in-office dispensing.Using data f...

SUBSPECIALTIES

Advertisement